
Disc Medicine Faces Class Action Probe After FDA Rejection
A 22% plunge in Disc Medicine’s stock price on February 13, 2026, has triggered a formal investigation by Rosen Law Firm. The legal action centers on allegations that the biotech company misled shareholders regarding the viability of its bitopertin drug program, which recently failed to secure FDA approval.


















